Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization

Affiliation:	1. Department of Radiology, Section of Interventional Radiology and Division of Interventional Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago IL;2. Department of Medicine, Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL;3. Department of Surgery, Division of Transplantation, Comprehensive Transplant Center, Northwestern University, Chicago, IL;4. Department of Radiology, Northwestern University Feinberg School of Medicine, Chicago IL;5. Department of Radiology, Jules Bordet Institute, Brussels, Belgium;6. Department of Digestive Oncology and Gastroenterology, Jules Bordet Institute, Brussels, Belgium;7. Department of Nuclear Medicine, Jules Bordet Institute, Brussels, Belgium

Abstract:	PurposeTo analyze long-term outcomes in patients bridged/downstaged to orthotopic liver transplantation (OLT) by transarterial chemoembolization (TACE) or yttrium-90 radioembolization (Y90) for hepatocellular carcinoma (HCC).Methods172 HCC patients who underwent OLT after being treated with transarterial liver-directed therapies (LDTs) (Y90: 93; TACE: 79) were identified. Pre-LDT and pre-OLT clinical/imaging/laboratory characteristics including United Network for Organ Sharing (UNOS) staging and alpha-fetoprotein values (AFP) were tabulated. Post-OLT HCC recurrence was assessed by imaging follow-up per standard of care. Recurrence-free (RFS) and overall survival (OS) were calculated. Uni/multivariate and sub-stratification analyses were performed.ResultsTime-to-OLT was longer in the Y90 group (Y90: 6.5 months; TACE: 4.8 months; p = 0.02). With a median post-OLT follow-up of 26.1 months (IQR: 11.1–49.7), tumor recurrence was found in 6/79 (8%) TACE and 8/93 (9%) Y90 patients. Time-to-recurrence was 26.6 (CI: 7.0–49.5) and 15.9 months (CI: 7.8–46.8) for TACE and Y90, respectively (p = 0.48). RFS (Y90: 79 months; TACE: 77 months; p = 0.84) and OS (Y90: 57% alive at 100 months; TACE: 84.2 months; p = 0.57) were similar. 54/155 patients (Y90: 29; TACE: 25) were downstaged to UNOS T2 or less. RFS hazard ratios for patients downstaged to ≤T2 versus those that were not were 0.6 (CI: 0.33–1.1) and 1.7 (CI: 0.9–3.1) respectively (p = 0.13). 17/155 patients (Y90: 8; TACE: 9) that were >T2 were downstaged to UNOS T2 or less (within transplant criteria). Distribution (unilobar/bilobar), AFP, and pre-transplant UNOS stage affected RFS on univariate analyses.ConclusionDespite longer time-to-OLT for Y90 patients, post-OLT outcomes were similar between patients bridged or downstaged by TACE or Y90. A trend towards improved RFS for downstaged patients was identified.

Keywords:	Transarterial chemoembolization Radioembolization Liver transplantation Downstaging OLT"} {"#name":"keyword" "$":{"id":"kw0030"} "$$":[{"#name":"text" "_":"orthotopic liver transplantation TACE"} {"#name":"keyword" "$":{"id":"kw0040"} "$$":[{"#name":"text" "_":"transarterial chemoembolization Y90"} {"#name":"keyword" "$":{"id":"kw0050"} "$$":[{"#name":"text" "_":"yttrium-90 radioembolization HCC"} {"#name":"keyword" "$":{"id":"kw0060"} "$$":[{"#name":"text" "_":"hepatocellular carcinoma LDT"} {"#name":"keyword" "$":{"id":"kw0070"} "$$":[{"#name":"text" "_":"liver directed therapy UNOS"} {"#name":"keyword" "$":{"id":"kw0080"} "$$":[{"#name":"text" "_":"United Network for Organ Sharing classification AFP"} {"#name":"keyword" "$":{"id":"kw0090"} "$$":[{"#name":"text" "_":"alpha-fetoprotein BCLC"} {"#name":"keyword" "$":{"id":"kw0100"} "$$":[{"#name":"text" "_":"Barcelona Clinic for Liver Cancer CP"} {"#name":"keyword" "$":{"id":"kw0110"} "$$":[{"#name":"text" "_":"Child-Pugh score ECOG"} {"#name":"keyword" "$":{"id":"kw0120"} "$$":[{"#name":"text" "_":"Eastern Cooperative Oncology Group IQR"} {"#name":"keyword" "$":{"id":"kw0130"} "$$":[{"#name":"text" "_":"interquartile range MAA"} {"#name":"keyword" "$":{"id":"kw0140"} "$$":[{"#name":"text" "_":"macroaggregated albumin MELD"} {"#name":"keyword" "$":{"id":"kw0150"} "$$":[{"#name":"text" "_":"model for end stage liver disease scoring system MRI"} {"#name":"keyword" "$":{"id":"kw0160"} "$$":[{"#name":"text" "_":"magnetic resonance imaging PVT"} {"#name":"keyword" "$":{"id":"kw0170"} "$$":[{"#name":"text" "_":"portal vein thrombosis mRECIST"} {"#name":"keyword" "$":{"id":"kw0180"} "$$":[{"#name":"text" "_":"modified Response Evaluation Criteria in Solid Tumors RFS"} {"#name":"keyword" "$":{"id":"kw0190"} "$$":[{"#name":"text" "_":"recurrence-free survival RFA"} {"#name":"keyword" "$":{"id":"kw0200"} "$$":[{"#name":"text" "_":"radiofrequency ablation US"} {"#name":"keyword" "$":{"id":"kw0210"} "$$":[{"#name":"text" "_":"ultrasound
本文献已被 ScienceDirect 等数据库收录！

设为首页 | 免责声明 | 关于勤云 | 加入收藏